High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A, Soleda M, Jimenez J, Hernandez-Losa J, Vivancos A, Felip E, Amat R.
Frigola J, et al. Among authors: cedres s.
J Immunother Cancer. 2022 Apr;10(4):e004197. doi: 10.1136/jitc-2021-004197.
J Immunother Cancer. 2022.
PMID: 35477861
Free PMC article.